Pliant Therapeutics (PLRX) Return on Capital Employed (2020 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Return on Capital Employed of 58.56% for Q1 2026, up 999.0% year-over-year from 5.33% in Q1 2025, and up 12.16% quarter-over-quarter from 66.67% in Q4 2025.
Pliant Therapeutics (PLRX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Return on Capital Employed for 7 consecutive years, with 58.56% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 999.0% year-over-year to 58.56%; the TTM figure through Mar 2026 stood at 58.56% (up 999.0% YoY), while the FY2025 annual figure was 53.06%, up 114.0% from the prior year.
- Return on Capital Employed climbed to 58.56% in Q1 2026 per PLRX's latest filing, from 66.67% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 28.51% in Q2 2023 and bottomed at 72.87% in Q2 2025.
- Historically, Return on Capital Employed has averaged 50.68% across 5 years, with a median of 52.29% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 3310 bps — and 2023, when it soared 3660 bps.
- Pliant Therapeutics' Return on Capital Employed stood at 37.41% in 2022, then gained by 1 bps to 36.99% in 2023, then tumbled by 59 bps to 58.84% in 2024, then declined by 13 bps to 66.67% in 2025, then climbed by 12 bps to 58.56% in 2026.
- Business Quant data shows PLRX's Return on Capital Employed at 58.56% in Q1 2026, 66.67% in Q4 2025, and 68.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Pliant Therapeutics | 69.66 Mn | 69.66 Mn | - | -54.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -54.23% |
| Mar 31, 2026 | -58.56% |
| Dec 31, 2025 | -66.67% |
| Sep 30, 2025 | -68.78% |
| Jun 30, 2025 | -72.87% |
| Mar 31, 2025 | -68.55% |
| Dec 31, 2024 | -58.84% |
| Sep 30, 2024 | -52.29% |
| Jun 30, 2024 | -44.04% |
| Mar 31, 2024 | -39.97% |
| Dec 31, 2023 | -36.99% |
| Sep 30, 2023 | -32.91% |
| Jun 30, 2023 | -28.51% |
| Mar 31, 2023 | -31.28% |
| Dec 31, 2022 | -37.41% |
| Sep 30, 2022 | -44.91% |
| Jun 30, 2022 | -65.11% |
| Mar 31, 2022 | -53.89% |
| Dec 31, 2021 | -46.26% |
| Sep 30, 2021 | -39.64% |